Skip to main content
. 2019 Jun 4;22(2):177–183. doi: 10.4103/aja.aja_38_19

Supplementary Table 1.

Univariable Cox regression models predicting survival outcomes in patients with upper tract urothelial carcinoma

Variables Cancer-specific survival Recurrence-free survival OS



HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (≥65 vs <65 years) 0.848 (0.641–1.122) 0.249 0.881 (0.696–1.115) 0.293 0.966 (0.748–1.246) 0.788
BMI (>25 vs ≤25, kg/m2) 0.848 (0.616–1.169) 0.315 0.947 (0.729–1.230) 0.681 0.917 (0.691–1.218) 0.551
Smoking status (former/current vs no) 0.844 (0.615–1.159) 0.294 0.864 (0.664–1.124) 0.275 0.878 (0.662–1.164) 0.364
Gender (male vs female) 0.824 (0.628–1.081) 0.163 0.857 (0.682–1.076) 0.184 0.876 (0.686–1.019) 0.290
Tumor side (right vs left) 1.089 (0.830–1.428) 0.538 1.063 (0.847–1.333) 0.601 1.051 (0.824–1.341) 0.687
Bladder cancer status 0.203 0.376 0.136
No Reference Reference Reference
Previous 0.345 (0.085–1.391) 0.134 0.903 (0.425–1.920) 0.792 0.297 (0.074–1.198) 0.088
Concomitant 1.205 (0.809–1.795) 0.360 1.263 (0.901–1.770) 0.176 1.198 (0.835–1.719) 0.327
Hydronephrosis (yes vs no) 1.249 (0.938–1.664) 0.128 1.401 (1.097–1.788) 0.007 1.342 (1.035–1.740) 0.026
Tumor location 0.556 0.508 0.675
Pelvicalyceal Reference Reference Reference
Ureteric 1.005 (0.729–1.384) 0.978 0.937 (0.715–1.229) 0.639 0.941 (0.704–1.260) 0.685
Both 1.217 (0.841–1.762) 0.298 1.152 (0.842–1.577) 0.377 1.118 (0.796–1.569) 0.521
Multifocality (yes vs no) 1.059 (0.736–1.524) 0.758 0.993 (0.727–1.358) 0.967 0.971 (0.692–1.361) 0.864
Surgical approach (Laparoscopic vs Open) 0.672 (0.485–0.932) 0.017 0.858 (0.662–1.114) 0.251 0.711 (0.529–0.956) 0.024
Tumor grade (high vs low) 3.558 (2.305–5.492) <0.001 2.278 (1.675–3.098) <0.001 2.847 (1.992–4.070) <0.001
pT stage <0.001 <0.001 <0.001
pTis, pTa, pT1 Reference Reference Reference
pT2 1.632 (0.966–2.757) 0.067 1.502 (1.011–2.233) 0.044 1.635 (1.045–2.558) 0.031
pT3 3.654 (2.372–5.629) <0.001 2.797 (2.005–3.901) <0.001 3.232 (2.222–4.702) <0.001
pT4 9.339 (5.921–14.729) <0.001 6.936 (4.811–9.998) <0.001 7.955 (5.327–11.881) <0.001
Lymph node status <0.001 <0.001 <0.001
pN0 Reference Reference Reference
pNx 1.496 (0.915–2.446) 0.109 1.505 (1.013–2.235) 0.043 1.507 (0.983–2.311) 0.060
pN+ 6.124 (3.525–10.638) <0.001 5.546 (3.484–8.831) <0.001 5.361 (3.260–8.814) <0.001
LVI (yes vs no) 2.726 (1.991–3.732) <0.001 2.211 (1.676–2.917) <0.001 2.511 (1.884–3.349) <0.001
Tumor size (>3 vs ≤3), cm 1.985 (1.439–2.739) <0.001 1.856 (1.425–2.418) <0.001 1.983 (1.486–2.645) <0.001
PSM (yes vs no) 2.319 (1.546–3.480) <0.001 1.865 (1.290–2.694) 0.001 2.118 (1.453–3.087) <0.001
Tumor architecture (Sessile vs Papillary) 3.675 (2.480–5.447) <0.001 2.500 (1.874–3.335) <0.001 2.928 (2.114–4.055) <0.001
CVH (yes vs no) 2.435 (1.825–3.248) <0.001 2.045 (1.595–2.622) <0.001 2.237 (1.722–2.906) <0.001
Adjuvant chemotherapy (yes vs no) 0.963 (0.731–1.268) 0.787 1.128 (0.896–1.420) 0.304 0.889 (0.693–1.139) 0.351
WBC (≥8.3 vs <8.3, ×109 l−1) 1.772 (1.305–2.407) <0.001 1.455 (1.111–1.904) 0.006 1.577 (1.189–2.092) 0.002
Platelet Count (≥230 vs <230, ×1099 l−1) 2.111 (1.592–2.799) <0.001 1.634 (1.276–2.091) <0.001 1.711 (1.317–2.222) <0.001
ALP (≥90 vs <90, U l−1) 1.782 (1.338–2.372) <0.001 1.396 (1.092–1.785) 0.008 1.497 (1.153–1.945) 0.002
LDH (> 220 vs ≤220, U l−1) 1.613 (1.145–2.272) 0.006 1.485 (1.109–1.989) 0.008 1.553 (1.141–2.113) 0.005
NLR (≥2.5 vs <2.5) 2.362 (1.749–3.190) <0.001 1.854 (1.458–2.358) <0.001 2.104 (1.617–2.737) <0.001
AGR (<1.45 vs ≥1.45) 2.381 (1.781–3.183) <0.001 1.818 (1.438–2.298) <0.001 2.141 (1.656–2.767) <0.001
Fibrinogen (≥4.025 vs <4.025, g l−1) 3.965 (2.998–5.243) <0.001 2.855 (2.265–3.598) <0.001 3.281 (2.559–4.206) <0.001

LVI: lymphovascular invasion; pT: pathological tumor; CVH: concomitant variant histology; PSM: positive surgical margins; WBC: white blood cell; ALP: alkaline phosphatase; LDH: lactate Dehydrogenase; NLR: neutrophil-to-lymphocyte ratio; AGR: albumin-to-globulin ratio; HR: hazard ratio; BMI: body mass index; OS: overall survival